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Background: This study intends to develop an efficient field‐in‐field (FiF) planning
technique with the Eclipse treatment planning system (TPS) to determine the feasi-
bility of using the Halcyon treatment delivery system for 3D treatment of breast
cancer.
Methods: Ten treatment plans were prepared on the Halcyon treatment planning sys-
tem and compared to the same patients’ clinically delivered TrueBeam plans which
used flattened 6 MV and 10 MV beams. Patients selected for this study were treated
via simple, tangential breast irradiation and did not receive radiotherapy of the supra-
clavicular or internal mammary lymph nodes. Planning target volumes (PTV) volumes
ranged from 519 cc to 1211 cc with a mean target volume of 877 cc. Several planning
techniques involving collimator, gantry rotation, and number of FiF segments were
investigated as well as the use of the dynamically flattened beam (DFB) — a prede-
fined MLC pattern that is designed to provide a flattened beam profile at 10 cm depth
on a standard water phantom. For comparison, the clinically delivered TrueBeam plans
remained unaltered except for normalization of the target coverage to more readily
compare the two treatment delivery techniques.
Results: Using the physician defined PTV, normalized such that 98% of the volume
was covered by 95% of the prescribed dose, the Halcyon plans were deemed clini-
cally acceptable and comparable to the TrueBeam plans by the radiation oncologist.
Resulting average global maximum doses in the test patients were identical between
the TrueBeam and Halcyon plans (108% of Rx) and a mean PTV dose of 102.5% vs
101.6%, respectively.
Conclusions: From this study a practical and efficient planning method for deliver-
ing 3D conformal breast radiotherapy using the Halcyon linear accelerator has been
developed. When normalized to the clinically desired coverage, hot spots were
maintained to acceptable levels and overall plan quality was comparable to plans
delivered on conventional C‐arm LINACs.
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1 | INTRODUCTION
Breast carcinoma is the most commonly diagnosed cancer in females.
About one in eight women in the United States (12.4%) will develop
invasive breast cancer over the course of their lifetime.1 Radiother-
apy, in conjunction with breast conservation surgery and chemother-
apy, plays a major role in the treatment of these cancers.2 Breast
radiotherapy is typically delivered by conventional 3D beams or
intensity modulated radiation therapy (IMRT). While IMRT is often
better suited to treat complex targets with involved lymph nodes,3
conventional 3D tangent beams continue to make up a large per-
centage of radiotherapy treatments with acceptable clinical out-
comes and widespread availability.
Recently, a compact ring‐shape medical linear accelerator (LINAC)
system, Halcyon (Varian Medical Systems, Inc.), was released. The
Halcyon system provides a single 6FFF beam with double‐stack mul-
ti‐leaf collimator (MLC) beam shaping system and faster gantry rota-
tion when compared with conventional C‐arm LINACs. TrueBeam
linear accelerators can deliver treatments at a maximum gantry rota-
tion of one rotation per minute vs four rotations per minute with
Halcyon. Maximum dose rate for a flattened 6 MV or 10 MV is
600 MU/min at isocenter for TrueBeam and 800 MU/min at isocen-
ter for the 6FFF beam provided on the Halcyon LINAC. Halcyon
was designed to address the global need for access to radiation ther-
apy with integrated imaging guidance, improved clinical efficiency,
and shorter installation and commissioning time as well as opera-
tional demands.4–6 However, the jawless design and unflattened
beam provide some challenges when creating breast 3D plans with
the FiF techniques. The jawless design might suggest that there is
increased out‐of‐field leakage dose to the patient compared to tradi-
tional C‐arm accelerators where jaws are needed to minimize this
out‐of‐field leakage. For example, Varian TrueBeam jaws collimate
the radiation that is not defined by the MLC aperture and minimize
interleaf leakage (radiation that permeates two adjacent leaves of
the same bank). There are two sets, one for each x‐y collimation
direction. They are 78 mm thick along the beam axis and are com-
prised of a tungsten alloy. Halcyon uses a double‐stacked MLC
arrangement with thicker leaves to account for a lack of jaws. The
Millenium‐120 MLCs fitted to most TrueBeams have 67‐mm‐thick
tungsten leaves, whereas the Halcyon has 77 mm thick leaves in
each bank, creating a combined thickness of 154 mm which results
in an average transmission factor of 0.0047 vs 0.015 for a Mille-
nium‐120 system. Because the MLCs are offset in the direction per-
pendicular to leaf travel, the interleaf leakage is attenuated by the
distal leaf bank. This design with thicker, offset leaves obviates the
need for jaws.
Typically, the use of 6 or 10 MV flattened beam and a set of sta-
tic MLC apertures can provide dose uniformity that is clinically
acceptable. To better control the dose homogeneity, the field‐in‐field
(FiF) technique is also often used in breast 3D planning.7–9 This
method uses multiple, planner‐defined MLC segments that reduce
hot spots and improve dose homogeneity. Traditional flattened
beams typically have flatness values under 3% for an isocentrically
placed phantom at 10cm depth. The 6FFF beams used by Halcyon
have flatness values of 10%–20% under the same setup conditions.
Using the conventional tangent beam arrangement on a breast target
would result in clinically unacceptable dose heterogeneity, usually
with large hot spots in excess of 135% of the prescription dose. If
the conventional FiF planning technique is directly applied, it typi-
cally requires a large number of static MLC segments to control the
hot and cold spots, increasing the complexity of the plan and
required planning time. In this study, we develop and evaluate a
planning strategy for the Halcyon accelerator to produce clinically
acceptable breast FiF plans using 6FFF beams. Differences in target
coverage and organ at risk (OAR) doses as a result of the 6FFF beam
quality were examined as well as patient‐specific quality assurance
(PSQA) delivery and analysis methods.
2 | METHODS
2.A | Radiotherapy delivery equipment
As shown in Fig. 1(a), Halcyon is a ring gantry LINAC with 100 cm
diameter bore size and is capable of providing a 6FFF beam utilizing
a compact gantry head design. This compact head allows a 1 m
diameter patient bore LINAC to be installed in the same room as
required for a conventional C‐arm LINAC. A typical C‐arm LINAC
has an effective “bore diameter” of approximately 80 cm, since the
physical measurement from the treatment head enclosure to
mechanical isocenter is 40 cm. Halcyon employs a staggered, dou-
ble‐stack MLC system, as illustrated in Fig. 1(b), which is the only
custom beam shaping device between the x‐ray source and the
patient. The MLC leaf width is 1.0 cm when projected at isocenter
with 100 cm source‐axis distance (SAD). The proximal and distal lay-
ers are offset, or staggered, by 50% of the leaf width such that the
effective resolution of the leaf stack pair becomes 0.5 cm at isocen-
ter. The maximum leaf speed is 5.0 cm/s at isocenter with 100%
interdigitation capability. There are 29 leaf‐pairs leafs in the proximal
layer and 28 leaf‐pairs in the distal layer with the maximum field size
of 28 × 28 cm2 at isocenter. One of the advantages of the double‐
stack design is that the combined transmission is less than 0.01%,
negating the need for physical jaws to reduce peripheral dose to
nontargeted organs.
2.B | Patient selection
Ten breast patients clinically treated with 3D FiF technique on C‐
arm LINACs (TrueBeam, Varian Medical System) from our institution
were randomly selected and anonymized. To confine the study to
feasibility of utilizing Halcyon for tangential breast radiotherapy,
patients with involved supraclavicular, axillary, or internal mammary
lymph node involvement were excluded. Across the 10 patients
selected, two physicians and three dosimetrists were involved in the
planning and approval of the treatment plans. This particular selec-
tion was performed to minimize potential bias due to a single plan-
ner. The prescribed dose to the PTV was either 4256cGy
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(266cGy × 16 fractions) or 5040cGy (180cGy × 28 fractions). Clini-
cally, 6 MV beams were utilized for eight of the 10 patients with
10 MV for the remaining two due to increased breast bridge separa-
tion (the distance between the medial and lateral borders of the
breast tissue at the middle of the breast). No couch kicks were uti-
lized in the clinical plans for any of the patients selected. Planning
target volumes (PTV) ranged from 519 cc to 1211 cc with a mean of
877.4 cc. Due to the intrinsic differences in MLC and beam quality,
the Halcyon patients were planned de novo but still using the same
gantry angles as the TrueBeam plans. Collimator rotation and MLC
shaped segments as well as respective field weighting differed from
the TrueBeam plans in order to produce homogeneous plans with
the FFF beam quality in as few steps as possible. For dosimetric
comparison with the Halcyon FiF plans, the plan normalization was
the only parameter modified on the clinically delivered TrueBeam
plans. Each plan was normalized such that 98% of the PTV received
at least 95% of the prescribed dose (V95%Rx = 98%).
2.C | Halcyon FiF plan generation
The Halcyon FiF plans were generated in Eclipse 15.6 treatment
planning system (Varian Medical Systems) with a standardized plan-
ning process specific to our clinic. The overall goal is to create as
few FiF segments in an attempt to balance planning time (<30 min
per patient) and complexity with clinically acceptable target coverage
(V95> 98%), and to minimize the global maximum dose (<115%) rela-
tive to the prescribed dose. The following sections 2.3.1‐2.3.5 high-
light the key steps and strategies during the planning process
2.C.1 | Field setup
Halcyon planning workflow starts with the clinically delivered, physi-
cian defined gantry angles and CT simulation‐defined isocenter (mid‐
bridge). The MLCs are fit to the beams‐eye‐view (BEV) contour of
the PTV with a 0.3 cm isotropic margin. At this point the BEV is
evaluated with the heart and PTV volume visualization turned on.
Typically in clinical plan, the physician will define the medial block
edge by placing a block margin around the medial aspect of the PTV
with consideration for minimizing heart dose. The block was
designed based on individual patient’s geometry. In this study, we
attempt to develop a simplified and standardized procedure to test
the feasibility of FiF technique on Halcyon. Therefore, the heart
block was not individually drawn for each patient. Also, at our clinic,
this physician defined block edge is not modified by the planner,
only MLCs from the other bank are moved to accomplish the FiF
modulation. In this study, we attempt to develop a simplified and
standardized procedure to test the feasibility of FiF technique on
Halcyon. This is not the case in this study and MLCs from either
bank were used to modulate dose as needed to achieve target cov-
erage and minimize OAR doses. Then approximately 2 cm of flash is
added on the nipple side of the target to account for potential respi-
ratory motion and setup uncertainty (Fig. 2). Dose is then computed
without normalization. Initial hotspots may exceed 140% or be as
low as 95% depending on the patient anatomy. The subsequent
planning steps focus on minimizing dose heterogeneity within the
beams eve‐view.
2.C.2 | Dynamically flattened beam sequence
The initial tangent fields incorporate the use of the TPS dynamically
flattened beam (DFB) option.10 The DFB is a predefined MLC
sequence unique to Halcyon which sweeps the MLCs, whereas the
beam is delivering dose to provide a flattened beam profile for a
fixed gantry beam delivery. This profile, however, is only flattened at
depth when delivered on a flat, homogeneous phantom. The DFB
sequence does not take into account patient anatomical variations.
The DFB tangents alone did not produce clinically acceptable dose
homogeneity for any of our tested patients (global Dmax < 115% of
prescription dose when the PTV was normalized such that
V98 = 95%). However, we found that the use of DFB tangents as
opposed to non‐DFB tangents markedly reduces the planning time
(a)
(a)
F I G . 1 . (a) Halcyon linear accelerator at Washington University in
St Louis. (b) Detectors‐eye‐view of the lower MLC leaf bank. MLC,
multi‐leaf collimator.
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by reducing the number of manually defined FiF segments that
would be required to achieve a similar, clinically acceptable dose dis-
tribution.
The DFB sequence (Fig. 3) is delivered by starting beam delivery
with the field fully blocked by proximal leaf bank B (X2). During con-
tinuous beam‐on, these closed leaves open in a predefined sequence
and park at the opposite field edge. Then the leaves of bank A (X1)
initiate their closing sequence until the beam is again fully blocked.
The DFB sequence is a binary option in the treatment planning sys-
tem and has no change in control points as a function of patient
anatomy, and only varies with field size. The number of monitor
units for a DFB field is significantly increased compared to an open
field that would deliver the same dose at treatment depth. This is
because the beam is continuously being delivered while the MLCs
sweep across so the high‐intensity portion of the beam is blocked to
make a flat beam. Table 3 in the Results section outlines the overall
MU difference in plans using the DFB vs TrueBeam. Details about
how the leaf sequence is programmed to produce a flat beam are
outside of the scope of this paper. Some details of DFB field are
provided by Constantin et al [10].
2.C.3 | Collimator rotation optimization
Optimal collimator rotation is needed to aid in subsequent modula-
tion of hot spots with the highest resolution achievable with the
MLC shaping system. A similar concept is used with TrueBeam, but
is usually slightly different due to the changes in hot spot extent and
location as a result of the FFF beam. The optimal rotation is deter-
mined after the initial dose calculation by analyzing the directions of
isodose falloff. This refers to the general direction between two or
more isodose lines. Practically, this is better determined through the
use of dose color‐wash visualization in the BEV with the range selec-
tion slider bar. Mitigation of hot spots with regard to the movement
(a)
(b)
F I G . 2 . (a) BEV of isotropic 0.3 cm margin, circular MLC fit to
PTV. (b) Flash added to anterior MLCs. BEV, beams‐eye‐view; MLC,
multi‐leaf collimator; PTV, Planning target volumes.
(a)
(b)
F I G . 3 . BEV of DFB sequence: (a) Proximal bank B (X2) opening
pattern; (b) Proximal bank A (X1) closing pattern. BEV, beams‐eye‐
view.
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limitations of the MLC is achieved by setting the collimator rotation
angle such that the direction of leaf motion is parallel to the isodose
falloff at the widest section of the breast in the medial‐lateral direc-
tion, typically at the level of the nipple (Fig. 4). Observed factors that
influence optimal collimator rotation are breast volume, anatomic tis-
sue distribution, and simulation setup conditions including slant
board angle.
After optimal collimator angle is determined, the MLCs are re‐fit-
ted to the PTV with the 0.3 cm isotropic margin and approximately
2 cm of flash added by manually selecting and dragging the leaves
of the anterior banks for the two DFB tangent beams. Once dose is
recomputed, the field weight of the DFB tangents is adjusted such
that the global Dmax is minimized and/or evenly distributed in the
craniocaudal axis.
2.C.4 | Manual FiF segments
The initial FiF segment typically utilized only the anterior leaf bank
for hot spot reduction. For ease of MLC placement, an isodose is
selected that yields a conventional FiF segment size in the BEV. In
our clinic, the planning strategy is to select an isodose that is
approximately 10%–15% lower than the hot spot but this technique
does not work well for the 6FFF beam quality and typically results
in a plan that has more FiF segments and required much more time
to plan. An “acceptable” FiF segment with this planning strategy
yields a 1–2 cm collective leaf motion from the previous segment
(Fig. 5). This method attempts to limit the number of segments while
keeping a dosimetrically meaningful number of monitor units (MU)
per segment. Institutionally, we have a minimum restriction of 5 MU
per segment for conventional LINAC FiF planning as well as Step‐
and‐Shoot IMRT delivery. This reduces the uncertainty due to non-
linearities in the delivery of monitor units. The Halcyon FiF planning
method has adopted this policy.
The process of selecting an isodose line as an MLC placement
guide is repeated approximately 2–4 times for each tangent field at
the initial gantry and collimator rotation angles resulting in 4–8 total
FiF segments for the plan. These FiF segments do not utilize the
DFB feature and are delivered in a step‐and‐shoot fashion with the
LINAC in a beam‐hold state during MLC movements. Generally
speaking, larger breast volumes will tend to require a higher number
of FiF segments to control hot spots and improve low dose cover-
age.
2.C.5 | Field weighting
Field weighting is performed after each segment is added and dose
recomputed. Weights are locked for all segments delivered at the
same gantry angle such that the FiF segment being weighted trades
monitor units with the initial DFB tangent beam of the same gantry
angle. This method attempts to keep the global hot spots evenly dis-
tributed in the craniocaudal direction. Appropriate field weight for
each segment is identified by actively monitoring the PTV coverage
in the dose volume histogram (DVH) viewer. Initial FiF segments
control the high‐dose slope of the DVH curve, whereas the final FiF
F I G . 4 . (a) Top row; Planning case in which the optimal collimator rotation was approx. 7 degrees. (b) Bottom row; Planning case in which
collimator rotation was not required.
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segments control the low‐dose coverage of the target volume. Fig-
ure 6 demonstrates how the shape of the curve changes as a func-
tion of field weight for a single initial segment. The optimal field
weight will vary based on MLC segment size, patient anatomy, and
initial dose distribution. This strategy can be applied to all FiF plan-
ning and should be used to minimize the number for FiF segments
needed and overall planning time.
In our testing, optimal field weight tends to straighten the DVH
curve as much as possible while minimizing the high dose tail.
2.C.6 | Plan normalization
The final planning step involves normalization. In this planning study
all patients were normalized such that 98% of the volume was cov-
ered by 95% of the prescribed dose. If the global Dmax was in excess
of 115% the normalization was reduced until the global Dmax was
below 115% of prescription. This situation was not encountered
with any of the 10 test plans. In clinical practice the target coverage
and normalization objectives are defined by physician preference. At
our institution, it is standard practice to achieve a PTV coverage of
V95% = 98% (V95 = 95% minimum acceptable) with a global Dmax less
than 115% (Fig. 7)
2.D | Deliverability and plan measurement
In order to test the deliverability of the ten plans, PSQA was per-
formed on each plan. First, ion chamber measurements were taken
with a PTW 31010, in a solid water phantom (15 cm3). Passing crite-
ria were percent dose deviation of less than ±3% from the expected
dose. Second, portal dosimetry was performed for each field. A com-
posite image was created, and gamma criteria was set according to
the recommendations of AAPM task group 218 (3% dose difference,
2 mm distance‐to‐agreement, global normalization, 10% thresh-
old with a tolerance level of 95% of pixels passing).11 Third, the
plans were delivered to a Delta4 Phantom+ (ScandiDos, Sweden).
The same criteria were set as for portal dosimetry on the composite
dose delivered to the phantom.
3 | RESULTS
3.A | Overall plan summary
All Halcyon plans were successfully generated within 30 min follow-
ing the standardized process developed and were evaluated by a
radiation oncologist that specializes in breast radiotherapy. Overall,
each Halcyon plan tested was deemed clinically acceptable. The
physician evaluated the organs at risk as well as target coverage via
isodose and DVH analysis. Table 1 summarizes the key results for
PTV dose across all ten patients. As mentioned before, for a fair
comparison, all Halcyon and TrueBeam plans in this study are nor-
malized such that 98% of the PTV volume is covered by 95% of the
prescribed dose. The mean global Dmax is the same for both the
TrueBeam and Halcyon plans (108.0%). The standard deviation for
the global Dmax in the plans is 2.5% for TrueBeam and 2.6% for Hal-
cyon. The mean PTV dose on the TrueBeam plans is hotter (102.5%)
compared with the Halcyon plans (101.6%).
OAR doses were analyzed for the heart, ipsilateral lung, and con-
tralateral lung. The mean dose for all TrueBeam plans was
97.96 cGy vs 149.58 cGy for the Halcyon plans. The average Dmax
of the heart for the left‐side target in Halcyon plans is 4450.1 cGy
compared to 4403.4 cGy for TrueBeam Plans; the average Dmax for
the heart is 360.0 cGy for Halcyon plans with right‐side target com-
pared to 474.9 cGy for TrueBeam Plans. Mean dose to the con-
tralateral lung dose increased from 26.41 cGy to 39.0 cGy for the
Halcyon plans. Ipsilateral mean lung dose decreased using the Hal-
cyon plans from 676.3 cGy to 569.4 cGy. The mean OAR dose sum-
mary is listed in Table 2.
The mean number of monitor units used for the Halcyon deliv-
ered plans was 732, whereas the TrueBeam delivered plans used
279. In Table 3, it is evident that for larger PTVs (particularly those
that were clinically treated with 10 MV) more FiF segments are nec-
essary with the Halcyon LINAC due to the shallower PDD10.
3.B | Sample plans
Figures 8 and 9 illustrate the dose distribution and DVH compar-
isons, respectively, of Halcyon and TrueBeam plans for test patient
05. This test plan is representative of a typical Halcyon plan in terms
of resultant coverage and global Dmax. This patient had a bridge
separation of 19 cm and a PTV volume of 687 cc which is within
one standard deviation (257 cc) of the average PTV volume of the
patients tested (877.4 cc). Qualitatively, the Halcyon plan has a more
F I G . 5 . BEV of the initial field. An arbitrary isodose line relative to
the maximum dose is chosen as a guide for placement of the MLC
leaves such that approx. 1–2 cm of collective leaf motion results.
BEV, beams‐eye‐view; MLC, multi‐leaf collimator.
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uniform dose in all three anatomical planes. The global Dmax was
1.5% lower (105.9% vs 104.4%). Ipsilateral mean lung dose
decreased from 375 cGy to 310 cGy, a 17.3% reduction. The DVH
in Figure 9 shows comparable PTV coverage and OAR sparing
between the two plans. Overall, the Halcyon plan only incorporated
1 more FiF segment compared to the TrueBeam plan (4 vs 3) (10).
F I G . 6 . (a) Initial DVH of PTV for patient 05 using various field weights for the first 2 FiF segments. (b) Zoomed view of high dose region of
DVH in Figure 6. For this segment, 4% field weight was optimal but optimal field weights will vary from patient to patient as well as segment
to segment. DVH, dose volume histogram; PTV, Planning target volumes.
F I G . 7 . DVH comparison of PTV
coverage using 6FFF tangent beams alone,
the DFB tangents alone, and the DFB
tangents paired with the manual FiF
segments. All three plans were normalized
such that 98% of the PTV volume was
covered by 95% of prescription. DFB,
dynamically flattened beam; DVH, dose
volume histogram; PTV, Planning target
volumes.
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TAB L E 1 Summary of Test Patient Results — PTV dose.
Patient PTV volume Site laterality TB Global Dmax H Global Dmax TB mean PTV H mean PTV
1 1069 cc Right 106.7% 111.5% 101.1% 102.9%
2 709 cc Left 108.8% 110.3% 103.3% 103.3%
3 519 cc Left 109.1% 106.6% 103.6% 99.8%
4 909 cc Right 106.4% 108% 103.1% 102%
5 687 cc Right 105.9% 104.4% 100.5% 100.5%
6 566 cc Left 113.2% 105.1% 107.3% 100.9%
7 1174 cc Right 105.1% 105.7% 99.9% 99.8%
8 801 cc Right 106.4% 107.2% 99.8% 101.5%
9 1129 cc Left 107.6% 111% 103.1% 101.6%
10 1211 cc Right 110.9% 110.3 % 103.7% 103.2%
Average 877.4 cc 40% Lt 60% Rt 108.0% 108.0% 102.5% 101.6%
Standard Deviation 257.4 cc n/a 2.5% 2.6% 2.3% 1.3%
PTV, planning target volumes.
















1 1069 cc 46.8 55.3 540.5 332.0 4.3 8.5
2 709 cc 225.6 353.2 574.6 583.1 170.2 187.3
3 519 cc 205.0 345.0 735.0 745.0 20.0 40.0
4 909 cc 45.0 70.0 610.0 460.0 5.0 15.0
5 687 cc 38.3 59.6 940.6 889.5 4.3 12.8
6 566 cc 149.0 280.9 919.3 872.5 8.5 25.5
7 1174 cc 46.8 63.8 740.5 655.4 34.0 46.8
8 801 cc 4.3 21.3 757.6 297.9 4.3 12.8
9 1129 cc 155.0 170.0 375.0 310.0 5.0 20.0
10 1211 cc 63.8 76.6 570.3 549.0 8.5 21.3
Average 877.4 cc 97.96 149.58 676.34 569.44 26.41 38.99
Std.
Dev.
257.4 cc 78.27 129.01 175.84 221.73 51.44 78.27
TB, TrueBeam; Hal, Halcyon; PTV, planning target volumes.
TAB L E 3 Energy, MU, and Segments used.
Patient PTV Volume TB Energy Hal Energy TB FiF Segments H FiF Segments TB MU Hal MU
1 1069 cc 6 MV 6FFF 5 7 302 MU 796 MU
2 709 cc 6 MV 6FFF 5 5 328 MU 736 MU
3 519 cc 6 MV 6FFF 4 6 244 MU 557 MU
4 909 cc 10 MV 6FFF 4 6 223 MU 574 MU
5 687 cc 6 MV 6FFF 3 4 300 MU 739 MU
6 566 cc 6 MV 6FFF 3 4 309 MU 713 MU
7 1174cc 6 MV 6FFF 6 6 306 MU 828 MU
8 801 cc 6 MV 6FFF 5 6 310 MU 844 MU
9 1129 cc 10 MV 6FFF 4 8 224 MU 677 MU
10 1211 cc 6 MV 6FFF 5 6 239 MU 857 MU
TB, TrueBeam; Hal, Halcyon; PTV, planning target volumes.
MORRIS ET AL. | 21
Figures 11 and 12 illustrate the dose distribution and DVH com-
parisons, respectively, for the most difficult plan encountered across
the 10 test patients. This patient had a bridge separation of 26 cm and
a PTV volume of 1129 cc which was the largest bridge separation and
second largest PTV volume in the study. This patient was clinically
treated using only 10MV beams. Qualitatively, the Halcyon does have
a less uniform dose but a clinically comparable PTV coverage based on
the DVH. The global Dmax was 3.7% higher (105.6% vs 109.7%). Ipsi-
lateral mean lung dose decreased from 941 cGy to 890 cGy, a 5.4%
reduction. The DVH in Figure 12 shows comparable PTV coverage
and OAR sparing between the two plans. Overall, the Halcyon plan
only incorporated 4 more FiF segments compared to the TrueBeam
plan (4 vs 8) (13).
3.C | Deliverability and Plan QA
All FiF plans were successfully delivered on Halcyon. Table 4 shows
the ion chamber measurements and gamma passing rates for all ten
plans. The average IC measurement had a percent dose deviation of
1.51% with the maximum deviation of 2.23%. All portal dosimetry
plans passed 3%/2 mm with 100% points passing. Average Delta4
passing rate was 99.4%.
4 | DISCUSSION
We demonstrated a FiF breast planning strategy utilizing a 6FFF
beam on the Halcyon platform. All ten plans were determined clinical
acceptable. Conventionally, FFF beams have not typically been used
in breast 3D planning due to the insufficient ability to deliver homo-
geneous dose to targets at depth. However, the percent‐depth‐dose
(PDD) for both 6 MV flattened (TrueBeam) and unflattened (Hal-
cyon) beams on central axis (CAX) are very similar to one another.
The PDD at a 10 cm depth with a 10 × 10 cm2 field size and
100 cm source‐to‐surface distance (SSD) for a 6 MV flattened beam
is nominally 66.7% vs 63.2% for a 6FFF beam. For comparison, a
10 MV beam has a nominal PDD of 73.2% under the same setup
conditions. This similar beam quality gives rise to the hypothesis that
with proper beam modulation, the nonflattened profile of a 6FFF
beam can be used to yield acceptable target heterogeneity while
F I G . 8 . Qualitative analysis for patient 05: Bridge separation = 19 cm. PTV Volume = 687 cc. PTV, planning target volumes
F I G . 9 . DVH comparison for patient 05:
Bridge separation = 19 cm. PTV
Volume = 687 cc. DVH, dose volume
histogram; PTV, planning target volumes.
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limiting hot spots of dose outside the targeted breast with a FiF
technique. This was even demonstrated for two patients that were
clinically treated with 10 MV beams to achieve the deep depth tar-
get coverage without exceeding physician defined global Dmax con-
straints. The focus of this paper is to establish a planning strategy
that makes best use of the technique available to the user of Hal-
cyon linac and to test the feasibility of applying FiF technique to
breast patient with jawless design and DSMLC (Double‐Stack MLC).
Therefore, we are not expecting to exactly mimic all beam parame-
ters as in clinical plans. The purpose of showing TrueBeam data is
F I G . 10 . BEV of the DFB and FiF segments for patient 05: Bridge separation = 19 cm. PTV Volume = 687 cc. BEV, beams‐eye‐view; DFB,
dynamically flattened beam; PTV, planning target volumes.
F I G . 11 . Qualitative analysis for patient 09: Bridge separation = 26 cm. PTV volume = 1129 cc. PTV, planning target volumes.
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not to determine which planning technique or modality is better
rather than providing some clinical references.
The primary organs at risk evaluated in this study were the heart,
ipsilateral lung, and contralateral lung. The mean heart dose
increased by an average of 51.6 cGy using the Halcyon plans
(98.0 cGy vs 149.6 cGy). Dmax to the heart for left sided targets
increased by 46.7 cGy (4403.4 cGy vs 4450.1 cGy) and Dmax
decreased for right sided targets by 114.9 cGy (474.9 cGy vs
360.0 cGy). This was due to the initial planning strategy of fitting
the primary DFB beams to the PTV with an arbitrary, isotropic
0.3 cm margin. This was chosen to simplify and standardize the plan-
ning process for this study. When visualized in the treatment plan-
ning system beams‐eye‐view, part of the heart is exposed to
the direct beam in the Halcyon plans as a result of this 0.3 cm mar-
gin. In clinical practice, the physician would aid the dosimetrist in
defining the block edge between the ipsilateral lung, heart and PTV.
With the individually designed heart block, the heart dose can be
further reduced in the Halcyon plans.
The contralateral lung dose was also higher with the Halcyon
plans by an average of 12.6 cGy (39.0 cGy vs 26.4 cGy). The uncer-
tainty in this value, however, is too high to make any deterministic
conclusions. It is well‐known that the uncertainty in calculating out
of field dose predicted by modern day treatment planning systems is
very high,12 especially at distances in excess of 10 cm from the field
edge. The accuracy of predicting peripheral doses with the Halcyon
TPS has also not yet been thoroughly evaluated.
Mean dose to the ipsilateral lung decreased with the Halcyon
plans by 15.8% (569.4 cGy vs 676.3 cGy). Similarly to the heart
dose, this result could be a function of the isotropic 3 mm margin
used in this study. However, the BEV of the clinical TrueBeam vs
Halcyon plans is nearly identical when evaluating the block edge
relative to the lung/chest wall interface. The softer spectrum of
the 6FFF beam is the likely explanation to decreased ipsilateral
lung dose. It is evident that the isodoses near the isocenter dip
toward the chest wall much more than the TrueBeam 6 MV and
10 MV plans. Lateral scatter and increased attenuation from the
F I G . 12 . DVH comparison for patient
09: Bridge separation = 26 cm. PTV
Volume = 1129 cc. DVH, dose volume
histogram; PTV, planning target volumes.
F I G . 13 . BEV of the DFB and FiF segments for patient 09. Bridge separation = 26 cm. PTV Volume = 1129 cc. BEV, beams‐eye‐view; PTV,
planning target volumes.
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medial and lateral lung regions are the most likely causes of a
reduction in ipsilateral lung dose when utilizing a 6FFF for breast
radiotherapy.
The Halcyon FiF plan requires more MU due to the use of DFB.
However, this will not increase the treatment delivery time com-
pared to TrueBeam plan. The ring gantry on Halcyon has the capabil-
ity to rotate faster at four rotations per minute (RPM) vs 1 RPM for
a conventional TrueBeam. The dose rate is also higher (800 MU/min)
than that of a 6 MV flattened beam (600 MU/min) on TrueBeam.
For the 10 patients tested, the computed delivery time based on
average the MU per plan and gantry rotation speed was 62.4 s for
Halcyon and 57.9 s for TrueBeam. The MLC movement speed was
not accounted for in this study but is not expected to drastically
change the previously mentioned delivery times. Setup times for
IGRT treatments will also affect total patient treatment times. Portal
images typically used for patient alignment pretreatment are not
available on the Halcyon. The options for imaging patient setup
include: MV 2D/2D (AP and Lateral), MVCBCT, and kVCBCT. Only
one option can be chosen during planning and it must be performed
daily. Due to the kVCBCT’s lower imaging dose and fast acquisition
time (as low as 16.7 s), we anticipate its wide usage. Image acquisi-
tion for Halcyon thus is faster than TrueBeam due to the fourfold
increase in gantry rotation speed.6 In conclusion, treatment delivery
times should be comparable between both treatment machines given
that patient setup times are significantly longer than beam on times
for this type of treatment.
Some limitations to this planning method exist. Firstly, only ten
patients’ plans were evaluated, although these ten patients reflect a
good laterality and PTV volume distribution, more cases will be
investigated in a future study to further characterize the benefits
and limitations of breast 3D FiF planning with Halcyon. All Halcyon
FiF plans passed the QA indicated the feasibility of the actual deliv-
ery of these plans. In our center, we perform hand calculations via a
commercial software as our QA approach for current clinical FiF
breast plans. On Halcyon, however, since we are using DFB tech-
nique, we propose to perform measurement‐based patient‐specific
QA, like IMRT cases, as our secondary check. Therefore, there is no
direct comparison with clinical plans on measurement‐based QA. As
Halcyon is still a relatively new modality and DFB is a new tech-
nique, we proposed to use measurement‐based patient‐specific QA
for the FiF plans in this study. This does require extra machine time
and effort from the physics and QA team compared to traditional
FiF plans on TrueBeam machines. It is also important to note that
not all breast cancer patients would be eligible for treatment on the
Halcyon unit. The maximum field size on halcyon is 28 × 28 cm2 at
isocenter, therefore patients with a large target size might not fit
into the beam portal design. Obese patients may also not be com-
patible even with the 100 cm diameter physical bore size. From this
planning study, for bridge separation distances exceeding 26 cm, it is
difficult to achieve adequate coverage at depth with the 6FFF beam
quality. In conventional multi‐port 3D breast radiotherapy, additional
fields are used to treat involved lymphatics such as the axillary, supr-
aclavicular, and internal mammary lymph nodes. Historically, couch
kicks (rotation of the treatment couch relative to the gantry) are
used to match field edges to avoid potential under or over‐dosage of
normal and targeted tissues. Halcyon is currently not capable of
rotating the couch to match beam divergence. One historic alterna-
tive to couch rotations is the half‐beam block technique.3 This tech-
nique utilized the jaws to eliminate beam divergence by placing one
of the jaws at the center of the field which will abut subsequent
treatment fields. The fact that Halcyon is jawless does not prevent
an equivalent approach using the onboard MLC. Leakage is signifi-
cantly reduced but not eliminated by the Halcyon MLCs compared
to the Millenium‐120 which is standard on most TrueBeams. The
biggest challenge of Halcyon compared to TrueBeam is the reduced
field size at isocenter paired with the increased limitations in isocen-
ter placement due to the physical bore. Future work will include
investigation of using Halcyon to treat these complex breast cases.
5 | CONCLUSION
In this study, a practical and efficient planning method for delivering
3D conformal breast radiotherapy using the Halcyon linear accelera-
tor has been developed. When normalized to the clinically desired
coverage, hot spots were maintained to acceptable levels and overall
plan quality was comparable to plans delivered on conventional C‐
arm LINACs. Using the original isocenter and gantry angles that were
used for TrueBeam delivery, the Halcyon patients would not have
experienced clearance issues as indicated by the TPS. Intrinsically,
the 6FFF beam’s slightly shallower PDD did not prohibit its use for
achieving deep target coverage while keeping superficial hot spots
below 115% of prescription.
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1 1.48 100 98.9
2 0.61 100 100
3 0.60 100 99.5
4 1.90 100 100
5 2.06 100 100
6 1.61 100 98.7
7 1.42 100 98.8
8 1.98 100 99.0
9 1.20 100 99.4
10 2.23 100 99.2
Average 1.51 100 99.4
IC = ion chamber, PD = portal dosimetry, D4 = Delta4. Dose difference
criteria was 3%, distance to agreement was 2 mm, and 95% gamma
passing rate.
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